Roche’s sBLA for Perjeta for adjuvant treatment of HER2-positive early breast cancer gets US FDA priority review status
Roche has announced the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority... Read More